Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

NCT04203160 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

75

Enrollment

OTHER

Sponsor class

Stopped Loss of funding

Conditions

Biliary Tract Cancer

Interventions

DRUG: CPI 613
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

University of Michigan Rogel Cancer Center